SITUS MBS303
IDR 10,000.00
mbs303 MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity
mbs303, MBS-303: CD20CD3Beijing Mabworks Biotech Co., Ltd. ()12.
Quantity: